What is ACTU's current stock price?

ACTU (Actuate Therapeutics Inc) is currently trading at $2.38 with a market cap of $56.9M.

What sector is Actuate Therapeutics Inc in?

Actuate Therapeutics Inc (ACTU) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ACTU a good stock to buy?

Analysts have a Buy consensus on ACTU with a price target of $21.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ACTU Actuate Therapeutics Inc

Healthcare

$2.38-1.65%ClosedMarket Cap: $56.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

14.80

P/S

0.00

EV/EBITDA

-2.26

DCF Value

$0.54

FCF Yield

-34.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-430.9%

ROA

-241.7%

ROIC

-521.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.6M	$—
Q4 null	$0.00	$-4.6M	$—
FY null	$0.00	$-22.2M	$—
Q3 null	$0.00	$-5.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$21.00

Target (Median)

$21.00

Target Range

$21.00 - $21.00

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-18

HC Wainwright & Co.Buy

2026-04-13

HC Wainwright & Co.Buy

2025-11-19

HC Wainwright & Co.Buy

2025-09-23

HC Wainwright & Co.Buy

2025-08-18

Trading Activity

Insider Trades

View All

Zabrowski Dandirector

SellFri May 22

THOMSON TODD Sdirector, 10 percent owner:

SellFri May 22

Sawhney Rogerdirector

SellFri May 22

RONNEBERG AMY Ldirector

SellFri May 22

Keyes Jason Adirector

SellFri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.93

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Peers

VOR